Xeris Biopharma Holdings (XERS) Interest Expenses (2020 - 2026)

Xeris Biopharma Holdings has reported Interest Expenses for 7 years, with the latest figure at $6.9 million in Q1 2026.

• For the quarter ending Q1 2026, Interest Expenses fell 5.54% year-over-year to $6.9 million; the trailing twelve-month figure through Mar 2026 stood at $28.7 million (down 6.6% YoY), and the FY2025 full-year result was $29.1 million, down 4.6% from the prior year.
• Interest Expenses for Q1 2026 stood at $6.9 million, down from $7.2 million in the prior quarter.
• The five-year high for Interest Expenses was $8.0 million in Q2 2024, with the low at $3.4 million in Q2 2022.
• Historically, Interest Expenses has averaged $6.4 million across 5 years, with a median of $7.0 million in 2023.
• Annual changes were most pronounced in 2022 — Interest Expenses soared 142.5% — and 2025, when it decreased 7.61%.
• Xeris Biopharma Holdings' Interest Expenses stood at $4.4 million in 2022, then jumped by 60.37% to $7.0 million in 2023, then gained by 9.79% to $7.7 million in 2024, then slipped by 6.92% to $7.2 million in 2025, then fell by 3.54% to $6.9 million in 2026.
• The last three Interest Expenses figures came in at $6.9 million (Q1 2026), $7.2 million (Q4 2025), and $7.3 million (Q3 2025), per Business Quant data.